References
- Reis G, Dos Santos Moreira-Silva EA, Silva DCM, TOGETHER investigators, et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health. 2022;10(1):e42–e51.
- Fluvoxamine Package Insert [Internet]. U.S. Food and Drug Administration. [cited 2022 Mar 7]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022235lbl.pdf
- Luo Y, Kataoka Y, Ostinelli EG, et al. National prescription patterns of antidepressants in the treatment of adults with major depression in the US between 1996 and 2015: a population representative survey based analysis. Front Psychiatry. 2020;11:35.
- Guo J, Zhu X, Badawy S, et al. Metabolism and mechanism of human cytochrome P450 enzyme 1A2. Curr Drug Metab. 2021;22(1):40–49.
- Ghannoum M, Wiegand TJ, Liu KD, on behalf of the EXTRIP Workgroup, et al. Extracorporeal treatment for theophylline poisoning: systematic review and recommendations from the EXTRIP workgroup. Clin Toxicol. 2015;53(4):215–229.
- van den Brekel AM, Harrington L. Toxic effects of theophylline caused by fluvoxamine. CMAJ. 1994;151(9):1289–1290.
- Sperber AD. Toxic interaction between fluvoxamine and sustained release theophylline in an 11-year-old boy. Drug Saf. 1991;6(6):460–462.
- Lexicomp® [Internet]. Lexicomp® online. [cited 2022. Jan 20];Available from: www.online.lexi.com/lco/action/interact
- Flockhart DA. Drug Interactions Table [Internet]. Indiana University Department of Medicine, Clinical Pharmacology. [cited 2022 Mar 7]; Available from: https://drug-interactions.medicine.iu.edu/MainTable.aspx